Exact Sciences` stock soars on news that Pfizer will market Cologuard test

Exact Sciences Corp. stock leaped more than 30 percent Wednesday after the Madison company announced that drug giant Pfizer will help sell Exact’s Cologuard non-invasive DNA stool test for colorectal cancer.

Pfizer will invest $20 million to $24 million a year, for a total of more than $65 million, between October 2018 and December 2021 to promote Cologuard. Exact will match those figures, on top of the annual $80 million it already pours into marketing....

See Also:

New Exact Sciences HQ envisions a more urban University Research Park


- - Volume: 6 - WEEK: 34 Date: 8/23/2018 8:14:18 AM -